The Effect of Sugar Load in IBS Patients Depending on Sucrase-isomaltase Genes

Region Skane40 enrolled

Overview

The investigators know that many patients with irritable bowel syndrome (IBS) have functional variants of genes coding for sucrase-isomaltase enzymes. The investigators will now examine whether these functional variants are associated with defect degradation of sucrose and associated gastrointestinal symptoms

The investigators have in a previous study included IBS patients for treatment with a starch- and sucrose reduced diet (SSRD). The investigators found a great improvement of symptoms. The investigators gene-tested those patients, and now have the full identification of all functional variants encoding sucrase-isomaltase enzymes. The investigators will invite patients from this previous study with normal genes and functional variants of genes. The patients will come fasting over night to the department of clinical research. The participants will ingest 75 g sugar dissolved in 0.8 dl water and flavored with lemon, to ingest during 5 minutes. After that, glucose will determined repeatedly up to 2 hours afterwards. At the same time, the participants have to assess their gastrointestinal sympotms on visual analogue scales (VAS). The investigators will compare the raise in b-glucose and symptoms between the groups of patients, divided into gene expression.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Sucrase-Isomaltase Deficiency Irritable Bowel Syndrome

Interventions

SugarDIETARY_SUPPLEMENT

75 g sugar dissolved in 0.8 dl water and flavored with lemon. Ingested during 5 minutes

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants of our previous clinical trial with SSRD diet (NCT03306381) Exclusion Criteria: * Difficulties in taking blood samples

Locations (1)

Department of Internal Medicine, Skåne University Hospital

Malmo, Sweden

Outcomes

Primary Outcomes

Changes from baseline of blood glucose levels

Measurement of glucose levels in blood drawn from an intravenous needle and analyzed at the Department of Clinical Chemostry

Time frame: From distribution repeatedly up to 2 hours

Change from baseline of gastrointestinal symptoms

Measurment of gastrointestinal symptoms on a visual analog scale measuring symptoms, range 0-100 mm, repeatedly at the same time points as blood glucose is measured. The higher scores, the worse symptoms.

Time frame: From baseline and up to 2 hours, at the same time points as blood glucose is measured

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.